ARS Pharma Submits SNDA For Neffy 1 Mg Dose For Pediatric Type I Allergic Reactions
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – ARS Pharmaceuticals Inc. (SPRY) announced the submission of a supplemental New Drug Application (sNDA) for neffy 1 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who weigh 15 to 30 kg. Pharmacokinetic (PK) data for neffy 1mg were
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-769720227_2400a-31d6e8ea286f4dea9c854eaf18af463c.jpg "Planning for Retirement? Start With These 5 Steps")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-how-to-trade-0dte-options-7481013-c9af6887219942dc9c8c9374963b51ec.jpg "How to Trade 0DTE Options")
